



Research Article

Generalized Rash in Severe Hospitalized COVID Patients: Correlation Between Histological Examinations, Drug Intake, Blood Interleukins Profile and Long-Term Follow-Up

Montserrat Fernández-Guarino^{1*}, V. Stewart², D. Fernández-Nieto¹, C. Moreno García del Real³, David González-de-Olano⁴, C. Blanco⁵, E. Solano Solares⁴, J. Martínez-Botas⁵, B. de la Hoz Caballer⁴, A. de Andrés-Martín^{2#}, L. García-Bermejo^{5#}

¹Dermatology Service, Hospital Universitario Ramón y Cajal. Instituto Ramón y Cajal de Investigación Sanitaria, Irycis, Madrid, Spain

²Immunology Service, Hospital Universitario Ramón y Cajal. Instituto Ramón y Cajal de Investigación Sanitaria, Irycis, Madrid, Spain

³Pathology Service, Hospital Universitario Ramón y Cajal. Instituto Ramón y Cajal de Investigación Sanitaria, Irycis, Madrid, Spain

⁴Allergy Service, Hospital Universitario Ramón y Cajal. Instituto Ramón y Cajal de Investigación Sanitaria, Irycis, Madrid, Spain

⁵Biomarkers and Therapeutic Targets Group, Instituto Ramón y Cajal de Investigación Sanitaria, IRYCIS, Madrid, Spain

⁶Biochemistry-Research Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (Irycis), Spain

#Both authors have contributed equally to this manuscript

*Corresponding author: Montserrat Fernández-Guarino, Dermatology Service; Hospital Universitario Ramón y Cajal. Instituto Ramón y Cajal de Investigación Sanitaria, Irycis, Madrid, Spain

Citation: Fernández-Guarino M, Stewart V, Fernández-Nieto D, del Real MG, González-de-Olano D, et al. (2024) Generalized Rash in Severe Hospitalized COVID Patients: Correlation Between Histological Examinations, Drug Intake, Blood Interleukins Profile and Long-Term Follow-Up. Int J Nurs Health Care Res 7:1569. DOI: <https://doi.org/10.29011/2688-9501.101569>

Received Date: 09 August, 2024; **Accepted Date:** 19 August, 2024; **Published Date:** 22 August, 2024

Abstract

Background: There have been few reports of cutaneous skin lesions in severe COVID-19 hospitalized patients, which exhibit different behavior compared to outpatients. Furthermore, a notable lack of rigorous studies exists. In this study, we included patients with generalized rash during the first wave of the pandemic for characterization. **Methods:** Hospitalized patients with severe confirmed pulmonary COVID-19 infection and a generalized cutaneous rash during the first wave in March-May 2020 were included. The study received approval from the ethics committee. Clinical presentation; histological examination, blood test, and complete blood interleukin profile were assessed. Special immunohistochemical investigations were conducted on the skin including CD3, CD163, IL1, IL6, IL10, IL12, and Spike protein, Nucleocapsid, VCAM1, E-Selectine and IT. Galpha. Long-term follow-up of the patient was performed through a phone call 24 months later. **Results:** A total 28 patients were studied and classified by histological examination into three groups: G1: perivascular dermatitis (18/28, 64%); G2: Drug reaction (7/28, 25%); and G3: Generalized exanthema and chilblain (3/28, 11%). The virus was not detected in the skin, by PCR and by immunohistochemical analysis and the interleukin expression in the skin were undetectable results. Vascular cell adhesion molecule 1 (VCAM1), E-selectine, and IT Galpha 5 were unpecific. G1 exhibited the least inflammation, G2 the most inflammatory, and G3 had previous inflammation. **Discussion:** Our data suggest that generalized exanthemas during severe SARS-Cov-2 infection exhibit unpecific finding and are similar to other rashes caused by inflammation. Drug reaction should be considered, as they accounted for 25% of the rashes. Further studies including higher number of patients are necessary.

Keywords: Skin; Covid infection; Cytokines; Sars-Cov2.

Introduction

During the initial stages and subsequent months, a flurry of publications emerged, with some likely being rushed, thereby overlooking the fundamental principles of scientific work, ethics, and research. During those months, the scientific community had an urgent need to understand and share what was happening with patients infected with SARS-CoV-2, and information was disseminated openly and rapidly as a top priority. This research was conducted meticulously, comprehensively, and in a multidisciplinary manner, encompassing various aspects of cutaneous manifestations in severely hospitalized COVID-19 patients with generalized rashes during the first wave. This encompassed histological examinations, immunohistochemical skin studies, blood tests, a comprehensive assessment of interleukin profiles, and long-term patient follow-up.

Reviews published about cutaneous manifestations in COVID-19 patients during 2020 mainly concur on categorizing outpatient manifestations into four groups [1], with a varying prevalence. These include inflammatory manifestation, exanthemas and urticarias, and vasculopathic skin lesion, such as chilblains and vasculitis [2-4]. Nevertheless, the cutaneous manifestations observed in hospitalized COVID-19 patients likely exhibit a different clinical presentation with an estimated 11% prevalence [5].

There have been published few reports of hospitalized patients with severe COVID-19 infection and cutaneous reactions [5,6]. Limitations have been identified in the study of dermatologic

COVID-19 manifestation in outpatients, as also noted by other authors [1,3,7].

These limitations included the selection of outpatients based solely on photographs without accompanying medical histories, the absence of confirmed SARS-Cov-2 infection, the lack of a cutaneous biopsy and eventually, the absence of an evaluation of a dermatologist. Rigorous studies were deemed necessary. However, perhaps, the most critical oversight, was the unconsideration of drug reaction as cause when describing exanthemas, being exanthemas the most reported [8,9]. The occurrence of cutaneous drug reaction in COVID-19 patient was rarely reported in most published series, despite these patients are under a, with high-risk of drug-induced exanthema, due to multiple drug treatment and viral infection. Additionally, patients were often classified without undergoing histological examination [10,11]. In the case of hospitalized patients, many of these limitations were not presented, as these patients were evaluated in a medical setting that allowed for complete examination and assessments by multidisciplinary medical team.

Despite the high number of reports about skin lesions in COVID-19, cutaneous manifestations were infrequent, with wide variability in estimation and in clinical presentation [1,11,12]. Interestingly, cutaneous manifestation decreased in subsequent waves of the pandemic, suggesting changes that occurred in the initial outbreak in relation to the cutaneous expression of SARS-Cov-2 infection [13].

The exact mechanism underlying the expression of SARS-Cov-2 infection on the skin is unknown. Various hypothesis has been suggested, with systemic inflammation and the cytokine release

being considered the main causes of cutaneous manifestations in COVID-19 patients [7]. However, other factors, as skin vascular activation should be considered depending on the type of cutaneous manifestation [2,9].

Not all reported patients underwent histological examination, and a lack of biopsies samples has been published [7]. Nonetheless, there is sufficient data to suggest the most frequent patterns and their relationship with the clinical manifestation, being perivascular lymphocytic infiltrated being the most commonly observed in patients with maculopapular exanthemas [14]. Regarding immunohistochemical studies, most of them yielded negative results in the detection of SARS-Cov-2 markers in the skin [15].

Many questions persist regarding how SARS-CoV-2 interacts with the immune system, with some similarities to other viral infections in certain cases, but marked differences in others, such as vascular involvement [16]. The immune response initiates against an external microorganism through cytokines produced by the innate immune system. Traditionally, interleukins 1 and 6 (IL-1 and IL-6) and tumor necrosis factor, particularly the alpha isoform TNF α , have been considered part of this group [17,18]. Macrophages are typically the primary cytokine producers in these early phases, although other cells like epithelial, endothelial, natural killer or dendritic cells can also produce them [19].

In contrast, coronavirus infection has shown a nearly exclusive increase in IL-6, with minimal elevation in the peripheral blood of the other two cytokines [18]. Unlike IL-1 or TNF α , IL-6 does not act by increasing the release of other cytokines but rather by enhancing their action on immune cells. The functions of IL-6 are particularly intriguing because it exhibits both inflammatory and anti-inflammatory properties. Mainly produced by macrophages and activated T lymphocytes (LT) [20], IL-6 influences B lymphocytes (LB) to promote antibody formation, stimulates LB and neutrophil production in the bone marrow, triggers the release of acute-phase reactants by hepatocytes, and inhibits the transformation of resting LT into regulatory LT. Meanwhile, the presence of transforming growth factor-beta (TGF- β) promotes the appearance of helper LT [21]. On the contrary, IL-6 induces anti-inflammatory activity by promoting the release of IL-10 and inhibiting IL-1 [17].

Subsequently, the specific immune response is driven by two subpopulations of helper T lymphocytes (Th), LTh1 and LTh17. LTh1 are releasers of gamma interferon (IFN γ), the production of which depends on IL-12 secreted by activated macrophages [19]. Although IFN γ has limited antiviral activity, it plays a crucial role in the Th1 response by maintaining macrophage activation. IL-17 is produced by LTh17 and plays a role in defense against

microorganisms, although the specific mechanism of action is not well-understood [21]. LTh17 are induced by the presence of IL-6 and TGF- β and sustained by IL-23 secreted by antigen-presenting cells (APCs) [15].

IL-10 is one of the most powerful anti-inflammatory cytokines, capable of inhibiting the production of many pro-inflammatory cytokines such as IFN γ , TNF α , IL-4, IL-6, IL-12, and growth factors [21]. It is primarily produced by B-lymphocytes (LB), monocytes-macrophages, dendritic cells, and certain subsets of regulatory T lymphocytes. IL-10's primary function is to mitigate the potential damage caused by inflammation [22]. IL-10 production is triggered by the presence of antigens and is elevated in the blood of patients with conditions like septic shock and autoimmune diseases [19]. Similarly, patients with coronavirus infections show a clear increase in IL-10 levels when peripheral blood IL-6 levels rise [7,18].

The presence of an antigen activates the immune response, but the immune system also initiates measures to regulate and control it (homeostasis) [23]. The main idea behind conducting multidisciplinary research that spans different medical specialties is because many of the skin manifestations are likely not directly induced by the virus but by the systemic activation of the immune system and the vascular endothelium. In fact, a portion of our study [24] demonstrates the expression of allergies to various drugs in the skin.

The goal of this study was to establish an accurate classification of cutaneous manifestations in severely hospitalized COVID-19 patients. Secondary objectives included describing generalized exanthemas, analyzing histological and immunohistochemical skin patterns, searching for the virus in the skin, evaluating interleukin profiles in peripheral blood, and tracking the long-term outcome of the patients.

Materials and Methods

Hospitalized patients with severe pulmonary confirmed COVID-19 infection and respiratory failure with a biopsied cutaneous generalized rash were selected between March and May of 2020 (33 patients). Generalized rash was considered disseminated lesions affecting two different body areas, including the trunk plus limbs or plus arms. The primary cutaneous lesions were classified as macules, papules, and nodules in the hands (chilblains). Days between the broke up of the lesions and the start of COVID-19 symptoms were measured (latency) and the duration of the cutaneous manifestations. Day 0 was considered the day of the spring up of the lesions.

This study was approved by the Ethics Committee (Number 197-20) and all patients gave verbal informant consent for undergoing

the biopsy and been included. The demographic data of the patients, the description of the cutaneous rash, hemogram, transaminases, reactive C protein (RCP), creatin phosphokinase (CPK) and D-dimmers were compiled (day 0±3 days). A history of drug intake before the reaction was assessed, considering treatment included in the 3 weeks before the broke up of the skin lesions. Patients who had previously received treatment with systemic corticosteroids or/and Tocilizumab were excluded.

The histological pattern of the erythematous rashes were analyzed by an expert dermatopathologist and classified into perivascular dermatitis with or without perianexial lymphocytic infiltrates, cutaneous small vessels vasculitis and drug reaction with interphase necrosis, necrotic keratinocytes and eosinophilic infiltrated. The distribution and immunohistochemical patterns were analyzed and classified as positive (+) or negative (-) and by distribution in interstitial, perivascular, and not-evaluable/technique failure. Skin biopsies were processed in conventional hematoxylin-eosin and immunohistochemical investigation

Levels of ILS in Skin Biopsies

In Fresh skin biopsies ILS were determined by qRT-PCR. Briefly, total RNA was isolated with TriPure Isolation Reagent® (1166716500, Roche Diagnostics). RNA concentration was determined using NanoDrop® (Thermo Fisher Scientific), 2 µg of RNA was used to obtain cDNA using Transcriptor First Strand cDNA Synthesis Kit (04897030001, Roche Diagnostics). 1ul of cDNA was used as the template for a quantitative PCR reaction with SYBR Green (11066420, SYBR Green I Master, Roche Diagnostics). PCRs were carried out in Lightcycler 480 equipment (Roche). For each sample and experiment, triplicates were made, and Ribosomal 28s mRNA levels were used as housekeeping for data normalization.

Immunohistochemistry for Markers Detection in Skin Biopsies

The markers selected for assessing activation and inflammation were assessed by immunohistochemistry. For this approach, 4 µm paraffin-embedded skin sections were treated with peroxidase blocking solution (Dako®) to inhibit endogenously peroxidase activity, blocked in 1% BSA-PBS, followed by incubation with CD3 (Abcam® Ref: ab16669), CD86(Abcam® Ref: ab243887), CD163 (Abcam® Ref: ab74604), VCAM (CD106) (LsBio® Ref:LS-C 172657), ITGalpha5 (Abcam® Ref: ab15036), and E-Selectina(Novus® Ref: NBP1-45545SS). Antibodies of cellular signaling of SARS-CoV2 were also tested, and finally SARS-CoV2 (alpha Rabbit) (Sino Biological®, ref: 40592-T62) and Nucleocapsid antibody (Rabbit Mab) (Sino Biological, ref:40143-R001) were performed. Secondary antibody conjugated with HRP (1:100, DAKO) was used and finally developed using DAB solution (DAKO).

Serum ILS Detection

Interleukins measured in peripheral blood included IL-6, IL-12, TNFα, INFγ, IL-17 and IL10. Controls were patients hospitalized with severe COVID-19 which did not develop skin lesions and matched in sex and age. Patients included were analyzed considering each control with the same patient, at the same time pre- and post-lesions.

Blood systemic levels of interleukins were assessed throughout flow cytometry, using the BD TM Cytometric Bead array (Human inflammatory cytokine CBA kit). Levels of IL6, IL12, TNF-alpha, IL10, IL-1B, IL8, INFγ and IL17 were measured at the start of the cutaneous lesions (day 0 ± 3 days) and days after the cutaneous lesions flare-up. From the Immunology data base of interleukins control patients without skin lesions were compiled. The inclusion criteria were SARS-COV-2infection, same age, gender, date of blood analysis (day 0 ± 3 days) and disease outcome (alive or die).

Statistical Analyses

The data was analyzed with ANOVA and U Mann-Whitney statistics tests. An analysis for each interleukin, leukocyte and the D Dimer was made between the different groups, including levels before and after the cutaneous lesion. Additionally, each group was compared with the COVID-19 control patients. A significant value of P <0.05 was considered. In the result we analyzed which group had the predominant profile of inflammatory (IL6, IL12, TNF-alpha, IL-1B, IL8, INFγ and IL17) or tolerogenic (IL10) interleukin and when, before or after the cutaneous lesion. All analyses were conducted using Graph Pad Prism® (GraphPad software, Inc).

Results

Clinical and histological results

Clinical and hematoxylin-eosin skin examination

Patients with severe COVID infection and respiratory failure with a rash during hospitalization were included. A total of 33 patients fulfilled the inclusion criteria (Table 1), 17 males and 16 females with a median age of 59.1 years (SD 16). The mean latency of the cutaneous lesions from the start of the covid-19 symptoms was 14,91 days (SD 9,88). The mean duration of the cutaneous affectation was 16.82 (SD 20.37). A total of 85%, 28 out of 33, of the patients presented a Generalized Exanthema (GE) with maculo-papular or edematous persistent papules (urticiform lesions) and 5 of them GE with chilblains. Regarding to the histological pattern, most of the patients presented perivascular dermatitis with or without perianexial dermatitis. Patients with generalized exanthemas was divided according to the histological examination for subsequent interleukin analysis in three groups:

G1: perivascular dermatitis 18/28, (64%); G2: Drug reaction 7/28, (25%); and G3: Generalized exanthema and chilblain, vasculitis, 3/28 (11%). Thus, histological features were considered the gold-standard for classified the group of patients instead of clinical examination (Flow-chart in Figure 1)

Description	Total of patients N=33
Medium age	59.1 (SD ¹ 16)
Sex	17 Males/16 Females
Timing (days)	Latency 14.91 (SD 9.88) Duration 16.82 (SD 20.37)
Type of cutaneous manifestation	Generalized exanthema ² 28/33 (85%) Generalized exanthema ² and chilblains 5/33 (15%)

¹SD: Standard deviation; ²Urticariiform and maculo-papular disseminated lesions; 3: Dermatitis includes perivascular and perianexial lymphocytic infiltrates; 4: Includes dermatitis and vasculitis in the small dermis vessels.

Table 1: Characteristics of the patients and histological examination of the skin lesions.




Figure 1: Flow-chart of the study and classification of the Groups of patients for Interleukin analysis; G1: perivascular dermatitis; G2: Drug reaction; G3: Generalized exanthema and chilblain, histological vasculitis.

Blood parameters analysis and immunohistology results

All patients with generalized exanthema (GE) (n=28, Table 2) have a previous history of drug intake, including Lopinavir/ritonavir, Dolquine, Ceftriaxone, Azitromicin, Ibuprofen or Paracetamol.

The data analysis of the parameters assessed in blood were Neutrophils 8301.52 (SD 4167.42), Lymphocytes 837.27 (SD 601.27), Platelets 156687.88 (SD 5645.54), Eosinophils 524.24 (SD 668.75), GPT 106.67 (SD 128.44), GOT 75.18 (SD 69.68), CPK 421.68 (SD 318.78), and D-Dimmers 3503.97 (SD 5645.54).

Citation: Fernández-Guarino M, Stewart V, Fernández-Nieto D, del Real MG, González-de-Olano D, et al. (2024) Generalized Rash in Severe Hospitalized COVID Patients: Correlation Between Histological Examinations, Drug Intake, Blood Interleukins Profile and Long-Term Follow-Up. *Int J Nurs Health Care Res* 7:1569. DOI: <https://doi.org/10.29011/2688-951.101569>

Description	Results
Drugs before GE ¹	Lopinavir/ritonavir, Dolquine, Ceftriaxone, Azitromicin, Ibuprofen, Paracetamol
Blood parameters	Neutrophils 8301.52 (SD ² 4167.42) Lymphocytes 837.27 (SD 601.27) Platelets 156687.88 (SD 5645.54) Eosinophils 524.24 (SD 668.75) GPT 106.67 (SD 128.44) GOT 75.18 (SD 69.68) CPK 421.68 (SD 318.78) D-Dimmers 3503.97 (SD 564.54)
¹ GE: generalized exanthema; SD: Standard deviation; +: positive.	

Table 2: Clinical, histological, and blood data of patients with severe Covid-19 infection and generalized exanthema (N=28).

The rest of the investigations in the skin yielded negative results or technique failures (Table 3). The PCR and interleukin detection in fresh skin samples was negative in four samples, and therefore the procedure was stopped. Immunohistochemical (IHC) skin investigation found CD3 and CD163 positive with interstitial expression in all patients (28/28, 100%). The antibodies IHC detection of Sars_Cov-2 particles in the skin were unspecific and not evaluable. The expression of VCAM1 (CD106), E-Selectine, and ITGalpha 5 could not be assessed due to technique failures. Those failures came up into an interruption of the planned initial studies.

Procedure/Technique	Reason
PCR ¹ of virus (4 fresh skin samples)	Negative, not detected
Immunohistochemical skin pattern	CD3 + interstitial (100%) CD163 + interstitial (100%)
IL1, IL6, IL10 and IL12 ² (4 fresh skin samples)	Negative, not detected
Spike/RBD coronavirus-19 detection (IHC) ³ (4 samples)	Unspecific Positive in controls
Nucleocapsid coronavirus-19 (IHC)	Negative Positive in controls
VCAM1 (IHC)	Unspecific Positive in controls
E-Selectine (IHC)	Technique failure
IT Galpha 5 (IHC)	Technique failure
¹ PCR: polymerase chain reaction; IL: interleukin; 3: immunohistochemistry; VCAM1: vascular cell adhesion molecule 1.	

Table 3: Failures of expression or procedures in skin samples of patients with severe COVID-19 infection and generalized exanthema.

Analysis of leukocytes and their populations per histological groups in patients with generalized exanthema.

Prior to the flare-up of the cutaneous lesions (Table 4)

Group 1 (G1-Dermatitis and rash) showed lower values of previous total leukocytes in comparison to Group 2 (G2-Drug reaction) and Group 3 (G3-Vasculitis) with significant differences ($p=0.05$ and $p<0.0001$), respectively.

Group 2 (G2-Drug reaction) presented more basal neutrophils and eosinophils than group 1, being statistically significant differences in neutrophils ($p=0.004$).

Group 3 (G3-Vasculitis): exhibited higher significant levels of neutrophils and eosinophils compared to Group 1 ($p<0.0001$ and $p=0.003$ respectively) and lymphocytes and monocytes compared to Group 2 ($p=0.01$ and $p=0.03$ respectively).

After the flare-up of the cutaneous lesions (Table 5).

G1-rash) presented more lymphocytes and monocytes than G2-drug (not statistically significant)

G2-Drug showed more neutrophils (not statistically significant) than G1-rash.

G3-vasculitis exhibited the higher total leukocytes levels in comparison with Group 1 and 2 ($p=0.0003$ and $p=0.0004$ respectively), mainly for the neutrophils ($p=0.008$ and $p=0.01$).

In the rest of the subpopulation, no significant differences were found between the three groups.

Before the injury	Group 1-rash	Group 2-drug	Group 3-vasculitis
Leukocytes	6698 ± 489,3	10020 ± 1432*	11999 ± 832,4*
Neutrophils	4665 ± 476,8	8343 ± 1395*	9249 ± 849,1*
Lymphocytes	1106 ± 93,33	889,6 ± 89,24	1453 ± 184,1*
Monocytes	507,1 ± 73,15	534,3 ± 49,13*	1111 ± 226,0*
Eosinophils	88,93 ± 29,93	135,0 ± 57,62	138,7 ± 40,01*
*Group 2 and 3 are statistically significant ($p<0.05$) toward group 1 in leukocytes and neutrophils; group 3 with group 2 in lymphocytes and monocytes and with group 1 in eosinophils and monocytes.			

Table 4: The leukocytes and their subpopulations comparing the different groups before the cutaneous lesion appearance.

After the injury	Group 1-rash	Group 2-drug	Group 3-vasculitis
Leukocytes	7639 ± 632,7	7770 ± 598,4	13031 ± 1017*
Neutrophils	5573 ± 560,6	6078 ± 569,9	10137 ± 1428
Lymphocytes	1463 ± 115,6	1190 ± 192,3	1934 ± 541,5
Monocytes	529,7 ± 55,47	470,5 ± 45,17	626,7 ± 115,6
Eosinophils	206,9 ± 49,73	227,6 ± 67,86	276,7 ± 108,8
*Group 3 is statistically significant ($p<0.05$) compared to groups 2 and 1 in leukocytes and neutrophils.			

Table 5: The leukocytes and their subpopulation comparing the different groups after the cutaneous lesion appearance.


Analysis of serum levels of inflammatory interleukins in patients with generalized exanthema or rash.

Interleukins before and after the cutaneous lesion appearance.


Figure 1a show the values of each histopathological group at pre-injury and post-injury moments. A tendency to inflammation was observed before the lesions in, G1-rash and G2-drug, while in G3-vasculitis the inflammation increased after the cutaneous lesion's appearance.

The differences between the inflammatory interleukins pre and post cutaneous lesions were analyzed as they exhibited a global different behavior depending on that moment. Regardless of histological group, IL-12, TNF α , INF γ and IL-17 increased after the onset of the cutaneous lesions, while IL-6 was higher before (Figure 1b). Table A1 (Appendix) shows the quantitative values of the analyzed interleukins.

The difference in the levels pre and post lesions of TNF α ($p < 0.001$) and IL-17 ($p < 0.003$) were found statistically significant.



1a



1b

Figure 1: Interleukins levels before and after the flare-up of the cutaneous lesions: (a) Considering all the pro-inflammatory interleukins by histological group, Group 1 (G1-rash), perivascular and perianaxial dermatitis, Group 2 (G2-drug), drug reaction and Group 3 (G3-vasculitis), cutaneous vasculitis; (b) Considering the different interleukins in all the groups together.

Interleukins Per Histological Groups

G1-Rash (Perivascular and perianaxial dermatitis): Showed higher values before lesions of IL-6, and IFN γ , with higher post-lesion values of IL12 and IL-17, without statistical significance (Figure 2a).

G²-Drug (Drug reaction): Exhibit higher pre-lesions values of IL6, IL12 and IFN γ were similar, being the IL6 statistically significant with the other groups (Figure 2b, $p = 0.05$ compared with group 1 and $p = 0.04$ compared with G3-vasculitis). After lesions IL17 and TNF α were increased, being the difference in TNF α significant ($p = 0.001$) compared to pre-lesions (Figure 2c). In both cases, the elevated after injure of IL-17 and TNF-alpha were significant respect to group 1 ($p = 0.05$ and $p < 0.0001$ respectively) and group 3 ($p = 0.002$ and $p = 0.02$ respectively) (Values in Table A2, Appendix).

G3-Vasculitis (Vasculitis): Higher values post-injury of IL-6, IL-12 and TNF α , were founded, being IL-6 differences statistically significant ($p=0.04$) (Figure 2d). The elevated of IL-6 post-injury in group 3 is higher and significative compared with group 1 ($p=0.04$) and group 2 ($p=0.02$).




Figure 2: Interleukins levels analyzed by histological groups and pre- and post-lesions appearance: (a) Group 1 (G1-rash), perivascular dermatitis; (b) IL-6 pre-injury compared between the different groups where statistically significant differences in group 2 (G2-drug) regarding groups 1 and 3 were found; (c) Group 2, drug reaction, with statistical differences in TNF α ; (d) Group 3 (G3-vasculitis) cutaneous vasculitis with statistical differences in IL-6.

Analysis of serum levels of IL-10 (anti-inflammatory interleukin) in patients with generalized exanthema

Interleukins levels before and after the appearance of cutaneous lesion, analyzed per histological groups.

G1-Rash and G2-Drug exhibit the same interleukin levels patterns: higher values before the lesion appeared with statistical significance $p=0.04$ and $p=0.02$ respectively, compared with the levels detected after the appearance of the skin lesion (Figure 3a). Regarding comparison between groups, highest values of IL-10 are detected in group 2 ($p=0.04$ respect to group 1) even when skin-lesion is evidenced. ($p<0.001$) (Figure 3b and 3c)

G \cdot -vasculitis: IL10 levels increase when skin lesion appeared, although, this difference is not statistically significant. In G3-vasculitis, the increase of IL-10 when lesion appeared is significantly higher in comparison to group 1 ($p=0.002$) and group 2 ($p=0.05$) (Figure 3c).




Figure 3: Levels of IL10 in the 3 histological groups. (a) levels before and after appearance of the lesion exhibiting statistical differences in G1-rash and G2-drug; (b) values of IL-10 comparing the different groups before skin lesion appearance, higher values were detected in G2-drug with statistical differences; (c) Post-appearance values of IL-10 comparing the different groups, higher values in group 3 exhibiting statistically significant differences between groups 2 and 1. Additionally, group 2 exhibited differences with group 1, statistically significant.

Analysis of serum levels of interleukins in patients with generalized exanthema compared with controls

Pro-inflammatory interleukins before and after the cutaneous lesion appearance, analyzed by per histological groups.

Before the cutaneous lesion: G1-rash and G2-drug present higher levels of IL-6 compared with controls. The difference is statistically significant in the case of group 2 ($p=0.009$) (Figure 4). G3-vasculitis exhibited similar levels to its control. In general, the controls exhibited higher levels of $TNF\alpha$ and $IFN\gamma$, even though the differences did not reach statistical significance.

After the cutaneous lesion: G2-drug presents highest values for IL-6 ($p=0.006$) compared to its controls and for IL-12 ($p=0.002$). For the other interleukins tested, the values are similar between controls and lesions, except for the $IFN\text{-}\alpha$ ($p=0.02$), IL-17 ($p=0.006$) and IL-6 ($p=0.01$) which presented higher in the controls from G1-rash1, G2-drug and G3 vasculitis respectively.




Figure 4: Levels of IL-6 in Group 2. Before and after the cutaneous lesion appearance, group 2 had the highest values of IL-6 with statistical differences regarding their controls.

Anti-inflammatory IL-10 before, after the cutaneous lesion, and per histological groups.

Pre-lesion: G2-drug and G3-vasculitis presents higher values of IL-10 compared with their controls being statistically significant for G3-vasculitis ($p=0.05$). G1-rash exhibits levels like its control.

Post-lesion: the only difference is found in the group 3 with highest levels of IL-10 ($p=0.016$).

Follow-up

Long-term follow-up of the patients was tracked by medical history data and by a phone call interview 24 months after the systemic cutaneous rash. Among the 33 patients, 20 were contacted, since two had died during the Covid episode (2020) and 11 were not localized. Two of the 20 patients contacted (10%), had presented new cutaneous lesion, one was diagnosed with chronic urticaria and the other had punctual flare of unspecific cutaneous skin lesion, solved without treatment, and not associated with any infection or possible trigger. Six of them (30%), had reinfection of the virus and the most remarkable was that 10 out of 20 (50%) referred persistent symptoms, nine commented fatigue and one forgetfulness. None of them had cutaneous reactions to drugs, vaccines neither thrombosis episodes.

Uncontacted (n=13) Followed (n=20)	
Symptoms	Percentage
New cutaneous lesions (n=2)	0.1
Cutaneous reaction to drug	0
New SARS-Cov-2 infection (n=6)	0.3

Persistent fatigue (n=10)	0.5
Reaction to vaccination	0
Thrombosis	0

Table 6: Long-term follow-up of the patients with generalized rash and severe-covid during the first stroke during 2020.

Discussion

A total of 28 patients with a generalized erythematous rash were thoroughly examined to ensure sample homogeneity. All of them were patients with severe COVID infection, hospitalized patients with respiratory failure during the first wave of the pandemic, and all of them had a cutaneous biopsy. Those inclusion criteria represented a bias as patient without cutaneous biopsy were excluded and patients with other types of cutaneous reactions. However, clinical cutaneous manifestation are subjective and varied during the infection. Thus, the histological pattern founded in the skin examination was considered the “gold-standard” for dividing the group of patients. Patients who had previously received treatment with systemic corticosteroids or/and Tocilizumab were excluded as Tocilizumab is a monoclonal antibody that competitively inhibits the binding of IL6 to its receptor, causing secondary elevated levels of the interleukin. This could also add a selection bias, as this treatment was prescribed to the more severe patients.

The initial group, the patients had an average age of 59 years, with an almost equal representation of both sexes. All patients had confirmed SARS-CoV-2 infection with severe pneumonia that required hospitalization. The onset of cutaneous lesions after the diagnosis of COVID-19 occurred at an average of 14.9 days (standard deviation 9.88), with an average duration of 16.82 days (standard deviation 20.87). These data indicate longer durations compared to those reported in outpatient cases, where the latency and duration tend to be shorter [25,26]. This difference may be attributed to the severity of the patients studied and the higher prevalence of drug reactions, which typically have longer durations and latencies [4].

Most authors suggest that generalized exanthemas in COVID-19 seems to be non-specific and clinically resemble other viral or inflammatory exanthemas, such as adult-onset Still’s disease or lupus [7]. A virus can trigger specific and non-specific cutaneous clinical manifestations. The significant variability in the clinical presentation of COVID-19 suggests that different mechanisms are at play in each type of presentation [25]. A classic example of a specific cutaneous clinical manifestation of a virus are herpes viruses, which causes concrete clinical manifestation and are detected in the skin for different techniques, as PCR, histological examination or Thanck diagnosis.

The reported prevalence of cutaneous manifestations in COVID-19 varies widely, ranging from 0.1% to 20%, depending on the source consulted [1]. Globally, it is estimated to affect approximately 1% of infected patients [7]. However, the distribution of prevalence is not uniform, with 96.9% of published cases with skin lesions coming from Europe, compared to just 3% from Asia [11]. The low frequency of skin involvement in coronavirus infection is still not fully understood, but it is suggested to be related to the absence of ACE2 and TMPRSS2 receptors in the skin, which serve as the virus's main entry points in other tissues such as the lungs or intestines [9,27].

Among the cutaneous manifestations, generalized maculopapular rash is one of the most common, ranking first or second in terms of frequency depending on the reported series. However, the clinical presentation in outpatient settings may not be directly comparable to that in hospitalized patients. Various manifestations have been described, including chilblains (40%), maculopapular rashes (22%), urticaria (9%), livedoid lesions (2%), and others [1]. In some studies, maculopapular rashes are the most frequently reported clinical presentation [4,25], potentially due to a tendency to report chilblains [3,7]. Nevertheless, many limitations have been observed in the published data on cutaneous manifestations in outpatients with COVID-19. Patients were often assessed through questionnaires and social media, with photographs, without involvement of dermatologists or access to medical histories [3,7].

A significant proportion (51.8%) of the published cases were only suspected and not confirmed, and only a minority underwent biopsies [12]. Authors agree that many of these cases were likely misclassified, but due to patient isolation, this was the method of study. However, certain questions remain unanswered, such as why drug reactions were not considered [3,8,10], and why the occurrence of cutaneous manifestations dramatically decreased in subsequent waves [13]. Possible reasons include reduced inflammation, vaccination efforts, and more standardized treatment protocols with fewer drugs in later phases of the pandemic.

This presented case series is the bigger in the literature revised among patient with severe COVID during the first wave following a correct histological classification. There are only a few case series regarding cutaneous manifestations in hospitalized severe COVID-19 patients [5,6]. Clinical experiences varied considerably, with a high prevalence of ulcers and vascular lesions, and exanthema accounted for 22% of observed lesions. While these studies were conducted in a hospital setting and thus more controlled, they still had limitations due to patient isolation, restricted ICU visiting policies, and the severity of the patients' conditions.

The primary challenge in diagnosing a generalized exanthema

in the context of a viral infection is distinguishing it from a drug reaction. Clues such as a history of drug intake, pruritus, or a delayed onset suggest a drug reaction [3]. However, a definitive diagnosis requires a compatible histological examination and further allergology studies. Interestingly, in contrast to most reports, in our patient series, 25% of the rashes were drug induced. Analytical blood tests showed typical parameters for severe COVID-19, such as elevated neutrophils, D-Dimers, and transaminases, but our patient group exhibited higher levels of eosinophils, likely due to the presence of drug-induced reactions in 25% of cases.

Histological examination of our patient group did not significantly differ from other viral exanthemas or published data, except for patients with drug reactions. The histopathology of generalized exanthema typically revealed a superficial perivascular lymphocytic infiltrate in the skin, sometimes with perianexial involvement. Vasculitis was observed in patients with chilblains, limited to the small dermal vessels, but suggesting a different mechanism or damage, probably more extended as hematies extravasation secondary to vasculitis was found. Patients with drug reactions exhibited typical histological features, such as necrotic keratinocytes and eosinophilic infiltrates.

Additional features described in the literature in COVID-19 patients with rashes include spongiosis, cell vacuolization [28], deep vascular dermatitis [29], lymphocytes surrounding vessels, or extravasated blood cells resembling a vasculitis pattern [30]. Routine CD3 and CD163 immunohistochemical examinations were performed in all biopsies and the results were similar across the board, making it challenging to distinguish mechanisms like drug reactions, viral infections, or inflammation. These findings suggest a continuous spectrum of skin involvement with varying degrees of severity. Notably, all patients in our study with chilblains, totaling only four, also had a generalized exanthema. In our group, patients with drug reactions did not exhibit vasculitis, which supports the idea that vasculitis or vascular involvement could be one of the more specific histological findings or clinical manifestation of coronavirus in the skin.

At the beginning of the study, we investigated SARS-CoV-2 expression by PCR in fresh skin biopsy samples from patients with generalized exanthema. However, after the first 4 samples tested negative, we discontinued the procedure. Other studies not focused on rashes but on conditions like chilblains [31] or papulo-squamous eruptions [32] in COVID-19 patients, also showed negative PCR results in skin samples. These findings suggest that the mechanism behind generalized exanthema in COVID-19 is not directly linked to the presence of the virus in the skin lesions.

To further understand whether the lesions were associated with the presence of the virus or an indirect activation of the immune

response in the skin, we conducted additional immunohistochemical examinations. Our carefully selected panel included measuring the expression of interleukins on the skin (IL1, IL10, IL6, and IL12) and SARS-CoV-2 proteins (such as the Spike protein), along with selected proteins involved in potential interactions between epithelial and endothelial cells and the virus, such as VCAM, selectin, and ITGalpha5. Finally, we could not demonstrate any particular mechanism of Sars-Cov-2 in the skin during systemic infection.

Severe COVID-19 infection can trigger a massive cytokine storm, primarily involving IL1, IL6, IL10, and IL12 [15,18]. However, we did not detect cytokine expression in the skin of patients with generalized exanthema. This supports the idea that these lesions result from mechanisms like other inflammatory diseases like lupus, antiphospholipid syndrome, or Still's disease [33]. Some other findings, such as complement activation, vessel necrosis, and skin thrombosis, have been observed but were typically associated with patients who had vasculopathy [34].

In the early days of the pandemic, some authors reported the presence of the Spike protein in skin lesions, determined by immunohistochemistry in cases of indirect cutaneous manifestations of COVID-19 [35]. In contrast, many studies have examined viral protein expression in skin lesions. For example, in one study involving 69 patients, extensive Spike protein deposition was found in relation to vasculitis and endothelial cell damage [36]. Recently, Marzano et al. [37] published different findings using digital PCR, indicating a 38% positive Spike protein expression in the skin, which did not seem to correlate with clinical expression. Based on these earlier findings, it's conceivable that the use of more sensitive and specific techniques could enable the detection of viral presence in skin lesions.

The remaining biomarkers we assessed did not provide insights into the mechanism, which is consistent with other reports. VCAM1 and Selectin have been considered markers of high mortality risk in COVID-19 patients with cytokine storms affecting the nervous system or lungs but not in the skin [38,39]. Both markers indicate endothelial damage and platelet interaction, typical phenomena in severe SARS-CoV-2 infections. Galpha is a protein involved in various physiological functions, including integrin activation, urotenin, and ECA function, which have been found to be part of the SARS-CoV-2 virus interaction in some systems but were not demonstrated in the skin [40].

In our blood samples, we exclusively studied the systemic levels of cytokines involved in the Th1 and Th17 inflammatory responses, along with IL-10. These were the cytokines used to guide the treatment of hospitalized patients during the initial wave of the coronavirus pandemic [41]. We did not evaluate other cytokines, which could be considered a limitation. We also did not analyze

classic Th2 responses, as they did not offer significant benefits or prognostic information in COVID-19 [42]. Additionally, an important limitation is the quantification of cytokines in hospitalized and severe patients, as the cytokines were not measured precisely when the skin lesions appeared, but rather with a time interval of several days. The number of patients ultimately included in the study could also influence the results. Despite these limitations, no other published studies have conducted a comprehensive analysis and correlation between skin manifestations, including histological classification, and the interleukin profile. This data could potentially yield interesting findings. Moreover, no deeper clinical data were presented regarding if these patients required mechanical ventilation, were on vasopressors, developed acute kidney injury, their length of hospitalization, and mortality rates. The study was focused of skin manifestation and these are all important variables when attempting to compare levels of systemic cytokines between patient groups and could be a limitation in the interpretation.

It has been generally hypothesized that skin rashes occurring in the context of viral infections are exclusively caused by the inflammatory response [9]. However, not all COVID-19 patients with a high inflammatory state develop skin lesions. Other factors may be at play, such as genetic predisposition or the virus itself. Not all skin manifestations of COVID-19 can be solely attributed to endothelial activation or vessel inflammatory damage. The interaction with drug intake should also be considered, especially since many patients, particularly in the early stages of the pandemic, received various drugs simultaneously. In fact, this group of patients with generalized rashes during severe COVID-19 infection underwent a thorough investigation for potential drug reactions, and 25% had biopsy results compatible with this diagnosis. After recovery, some of them tested positive in clinical and in vitro tests for drug allergies [24].

No correlation was found between the levels of interleukins, the interleukin profile, and the systemic or vascular damage or skin manifestations in the studied patients. No specific risk factors or situations were identified as enhancers, whether from the blood analysis, demographic data, or histological staining.

This multidisciplinary study allowed us to classify patients referred to the Dermatology department into three groups based on histological alterations observed in skin biopsies by pathologists, with the aim of describing different pathogenic patterns. The histological classification served as the "gold standard" and resulted in three groups: group 1 (G1-rash with dermatitis, group 2 (G2-drug) with drug reactions, and group 3 (G3-vasculitis) with cutaneous vasculitis. Interleukin profiles were studied in these three groups, both before and after the appearance of skin lesions, to assess differences. Interestingly, G1-rash and G2-drug exhibited

higher proinflammatory levels before the onset of skin lesions, while G3-vasculitis showed higher values after the appearance of cutaneous lesions.

When each pro-inflammatory interleukin was analyzed separately, we observed different behavior patterns among them and between the groups. IL-6 consistently appeared as the most elevated interleukin in all groups, as is typically found in patients with COVID-19 infection [9], regardless of whether they had skin lesions or not [15]. As cutaneous lesions progressed, like the systemic immune response, the pattern of interleukins changed, with TNF α ($p < 0.04$) and IL-17 ($p < 0.03$) showing the greatest increases post-injury. Both TNF α and IL-17 were potentiated by the presence of IL-6, which is closely related to them, except in G3-vasculitis patients, where IL-6 also increased after the cutaneous lesions.

G1-rash was founded the least inflammatory group, with the lowest values of leukocytes, sub-populations, and pro-inflammatory interleukins. In this group, genetic influence or other factors may have predisposed individuals to cutaneous reactions.

G2-drug was presented as the most inflammatory, particularly before the flare-up of the lesions, although many interleukins maintained elevated levels post-injury compared to the other groups. However, most of them, except for TNF α , tended to decrease once the lesion had developed. In these patients, the presence of inflammation itself may play a more important role in the pathogenesis of cutaneous manifestations, influenced by factors such as drugs or genetic predisposition. In any case, high levels of interleukins were more intensely related to this group, likely originating from neutrophils even before the appearance of skin lesions.

G3-vasculitis represented a different scenario from the other groups. Notably, IL-6 levels increased after the onset of lesions ($p = 0.04$), possibly contributing to the increase in neutrophils observed post-injury. Another interesting finding was the increase in IL-12 after the appearance of cutaneous lesions, another interleukin produced by innate immune system cells in response to viral antigens. IL-12 primarily promotes differentiation towards IFN-producing Th1 cells in the presence of viruses. Based on this, it can be inferred that in G3-vasculitis, skin involvement is directly related to local activation of the vascular endothelium due to the presence of various factors, including the virus. When the virus is eliminated, it is no longer found in the lesions, but the result of the activation persists. Additionally, G3-vasculitis showed a significant increase in the number of neutrophils after the appearance of lesions compared to its previous values, indicating acute inflammation and potential cell recruitment by the endothelium [43]. This observation aligns with the vascular lesions found in the histological study.

IL-10 is an anti-inflammatory interleukin and showed the same pattern between the groups: G1-rash and G2-drug presented a decrease after the start of the lesion, statistically significant in both groups ($p = 0.04$ and $p = 0.02$ respectively), while in G3-vasculitis, IL10 raised after lesions appearance. Once again, the highest values were presented by G2-drug except at the post-injury level, which, as occurred with IL-6, spikes in G3 patients. In G1 and G2-drug, this data could support the direct relationship of inflammation with the pathogenesis of skin involvement. In G3-vasculitis, this great elevation of IL-6 could be responsible for the elevation of IL-10 itself and be part of the physiological response to the immunological stimulus. After facing intense systemic inflammation, an increase in IL-10 counteracts the harmful effects. This fact was also observed in patients with COVID-19 [44].

Patients with severe COVID-19 infection and cutaneous lesions were compared with those without cutaneous lesions, given that many of the alterations observed in the pattern of ILs were seen in patients without cutaneous manifestations. COVID-19 positive control patients were selected among severe coronavirus infection, regardless of the skin lesion, and once again, G1-rash and G2-drug patients behaved differently from G3-vasculitis and had higher IL-6 values than couplets COVID-19 controls, being statistically significant in G2 ($p = 0.009$). At the post-injury level, the only one that persists in clearly higher values was G2-drug ($p = 0.006$) with respect to controls. On the other hand, G3-vasculitis maintained values like controls after injury... For years, the activity of pro-inflammatory ILs has been related to the pathogenesis of vascular damage, with special emphasis on the role of IL-10 as a protector [22,23]. Maybe that is why in G3-vasculitis patients, due to the activation of the vascular endothelium, the values of this IL rise much more than in the rest.

Long-term follow-up was conducted 24 months after the generalized rash through phone interviews. A total of 20 patients were contacted, and no specific symptoms were reported, except for 50% of the patients who mentioned tiredness without a diagnosis of post-COVID syndrome [20] and thus without establishing causality.

In conclusion, all these findings described and characterized for the first time skin lesions associated to SARS-Cov2 infection, pointing out new factors contributing to the appearance and the resolution of the lesions, related and unrelated to the viral presence.

Conclusions

This study aimed to characterize generalized exanthematic rashes in severe hospitalized COVID-19 patients during the first wave of the pandemic. The mechanism underlying these rashes appears similar to unspecific rashes seen in other viral infections, supported by histological findings and the absence of the virus in the skin.

Notably, 25% of the patients were diagnosed with a drug reaction.

The highly inflammatory systemic state in COVID-19 patients alone is suggested as the not unique cause of the appearance of the skin lesions. Before the appearance of lesions, IL-6 exhibited higher levels and possibly played a central role. However, after the lesions appeared IL-17 and TNF- α appeared to be predominant. The presence of pharmacological interactions, along with active inflammation and viral infection, was not sufficient to trigger skin lesions, suggesting the involvement of other factors not included in the study. Among these groups of patients, patient with a cutaneous drug reaction (G2-drug) displayed the highest level of inflammation, suggesting that inflammation could be a significant contributing factor to the development of cutaneous lesions. In contrast, patients with vasculitis (G3-vasculitis) showed a greater elevation in cytokines after the onset of lesions, which might be due to direct activation of the local vascular endothelium. The elevated levels of IL-10 in patients with vasculitis (G3-vasculitis) patients, also when compared to controls, could support the idea that vascular endothelial damage could be a significant contributor to the lesions in this group.

To the best of our knowledge, this is the first study to assess serum interleukin profiles and tissue markers in patients with severe hospitalized COVID-19 patients and cutaneous manifestations. Based on our results, the clinical, histological, and systemic immunological behavior of patients with severe COVID-19 and cutaneous skin lesions during the first wave of the pandemic in our hospital resembled the behavior observed in other viral rashes. In this context, the interaction of other factors as, genetic factors, other organ involvement and drug intake should be considered. Further studies, including larger number of patients, are necessary to confirm our findings and explore the involvement of additional factors in COVID-19 associated skin lesions but they could not be repeated in the first wave.

Author Contributions

For research articles with several authors, a short paragraph specifying their individual contributions must be provided. The following statements should be used. “Conceptualization, MFG, MLGBX.X and Y.Y, Methodology, X.XCBA, software, X.X, Validation, X.X, Y.Y, Z.Z. Formal analysis, MFG, CBAX.X, Investigation, MFG, CBAX.X, Resources, MFG, MLGBX.X, Data curation, MFGX.X, Writing-original draft preparation MFG, MLGB, X.X, Writing-review and editing, MFG, MLGBX.X, Visualization, MFGX.X, Supervision, MFG, MLGB X.X, Project administration, MFGX.X, Funding acquisition, MFG, MLGBY.Y All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by FONDO SUPERA COVID19, grant identification “Cutinmfarm” by the SANTADER FOUNDATION and associated to the Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) and Alcala University (AU) of Madrid (Spain).

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of HOSPITAL UNIERSITARIO RAMÓN Y CAJAL (protocol code 197/20, 22/06/2020).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

We encourage all authors of articles published in MDPI journals to share their research data. In this section, please provide details regarding where data supporting reported results can be found, including links to publicly archived datasets analyzed or generated during the study. Where no new data were created, or where data is unavailable due to privacy or ethical restrictions, a statement is still required. Suggested Data Availability Statements are available in section “MDPI Research Data Policies” at <https://www.mdpi.com/ethics>.

Acknowledgments

In this section, you can acknowledge any support given which is not covered by the author contribution or funding sections. This may include administrative and technical support, or donations in kind (e.g., materials used for experiments).

Conflicts of Interest

Declare conflicts of interest or state, “The authors declare no conflict of interest.” Authors must identify and declare any personal circumstances or interest that may be perceived as inappropriately influencing the representation or interpretation of reported research results. Any role of the funders in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript; or in the decision to publish the results must be declared in this section. If there is no role, please state, “The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results”.

References

1. Jia JL, Kamceva M, Rao SA, Linos E (2020) Cutaneous manifestations of COVID-19: A preliminary review. *J Am Acad Dermatol* 83:687-690.

Citation: Fernández-Guarino M, Stewart V, Fernández-Nieto D, del Real MG, González-de-Olano D, et al. (2024) Generalized Rash in Severe Hospitalized COVID Patients: Correlation Between Histological Examinations, Drug Intake, Blood Interleukins Profile and Long-Term Follow-Up. *Int J Nurs Health Care Res* 7:1569. DOI: <https://doi.org/10.29011/2688-951.101569>

2. Recalcati S (2020) Cutaneous manifestations in COVID-19: a first perspective. *J Eur Acad Dermatol Venereol* 34: e212-e213.
3. Marzano AV, Cassano N, Genovese G, Moltrasio C, Vena GA (2020) Cutaneous manifestations in patients with COVID-19: a preliminary review of an emerging issue. *Br J Dermatol* 183: 431-442.
4. Genovese G, Moltrasio C, Berti E, Marzano AV (2021) Skin Manifestations Associated with COVID-19: Current Knowledge and Future Perspectives. *Dermatology*. 237: 1-12.
5. Do MH, Stewart CR, Harp J (2021) Cutaneous Manifestations of COVID-19 in the Inpatient Setting. *Dermatol Clin* 39: 521-532.
6. Rekhman S, Tannenbaum R, Strunk A, Birabakaran M, Wright S, et al. (2021) Eruptions and related clinical course among 296 hospitalized adults with confirmed COVID-19. *J Am Acad Dermatol* 84: 946-952.
7. Criado PR, Abdalla BMZ, de Assis IC, van Blaricum de Graaff Mello C, Caputo GC, et al. (2020) Are the cutaneous manifestations during or due to SARS-CoV-2 infection/COVID-19 frequent or not? Revision of possible pathophysiologic mechanisms. *Inflamm Res* 69: 745-756.
8. Martinez-Lopez A, Cuenca-Barrales C, Montero-Vilchez T, Molina-Leyva A, Arias-Santiago S (2020) Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist. *J Am Acad Dermatol* 83: 1738-1748.
9. Garduno-Soto M, Choreno-Parra JA, Cazarin-Barrientos J (2021) Dermatological aspects of SARS-CoV-2 infection: mechanisms and manifestations. *Arch Dermatol Res* 313: 611-622.
10. Solano-Solares E, Chica-Guzman V, Perez-Allegue I, Cabrera-Hernandez R, Fernandez-Guarino M, et al. (2022) Role of Drug Hypersensitivity in the Cutaneous Manifestations of SARS-CoV-2 Infection. *J Investig Allergol Clin Immunol* 32: 218-220.
11. Tan SW, Tam YC, Oh CC (2021) Skin manifestations of COVID-19: A worldwide review. *JAAD Int* 2: 119-133.
12. Sharma S, Raby E, Prasad Kumarasinghe S (2021) Cutaneous manifestations and dermatological sequelae of Covid-19 infection compared to those from other viruses. *Australas J Dermatol* 62: 141-150.
13. Fernandez-Nieto D, Ortega-Quijano D, Suarez-Valle A, Jimenez-Cauhe J, Jaen-Olasolo P, et al. (2021) Lack of skin manifestations in COVID-19 hospitalized patients during the second epidemic wave in Spain: a possible association with a novel SARS-CoV-2 variant - a cross-sectional study. *J Eur Acad Dermatol Venereol* 35: e183-e185.
14. Reymundo A, Fernaldez-Bernaldez A, Reolid A, Butron B, Fernandez-Rico P, et al. (2020) Clinical and histological characterization of late appearance maculopapular eruptions in association with the coronavirus disease 2019. A case series of seven patients. *J Eur Acad Dermatol Venereol* 34: e755-e757.
15. Ionescu MA (2022) COVID-19 skin lesions are rarely positive at RT-PCR test: the macrophage activation with vascular impact and SARS-CoV-2-induced cytokine storm. *Int J Dermatol* 61: 3-6.
16. Gawaz A, Guenova E (2021) Microvascular Skin Manifestations Caused by COVID-19. *Hamostaseologie* 41: 387-396.
17. Abbas AK, Lichtman AH, Pillai S (2021) Cellular and Molecular Immunology, 10th Edition edn. United States: Elsevier Saunders.
18. Gallman AE, Fassett MS (2021) Cutaneous Pathology of COVID-19 as a Window into Immunologic Mechanisms of Disease. *Dermatol Clin* 39: 533-543.
19. Rich RRFTA, Shroeder HW, Weyand CM, Corry DB, Puck JM (2022) *Clinical Immunology*. Elsevier.
20. Fawzy NA, Abou Shaar B, Taha RM, Arabi TZ, Sabbah BN, et al. (2023) A systematic review of trials currently investigating therapeutic modalities for post-acute COVID-19 syndrome and registered on WHO International Clinical Trials Platform. *Clin Microbiol Infect* 29: 570-577.
21. Stiehm ER: Joseph A (2012) Bellanti (ed) immunology IV: clinical applications in health and disease. *J Clin Immunol* 32: 647.
22. Barcelos ALV, de Oliveira EA, Haute GV, Costa BP, Pedrazza L, et al. (2019) Association of IL-10 to coronary disease severity in patients with metabolic syndrome. *Clin Chim Acta* 495: 394-398.
23. Perez Fernandez R, Kaski JC (2002) [Interleukin-10 and coronary disease]. *Rev Esp Cardiol* 55: 738-750.
24. Fernandez-Lozano C, Solano Solares E, Elias-Saenz I, Perez-Allegue I, Fernandez-Guarino M, et al. (2023) Value of the Lymphocyte Transformation Test for the Diagnosis of Drug-Induced Hypersensitivity Reactions in Hospitalized Patients with Severe COVID-19. *Int J Mol Sci* 24.
25. Kaya G, Kaya A, Saurat JH (2020) Clinical and Histopathological Features and Potential Pathological Mechanisms of Skin Lesions in COVID-19: Review of the Literature. *Dermatopathology (Basel)* 7: 3-16.
26. Daneshgaran G, Dubin DP, Gould DJ (2020) Cutaneous Manifestations of COVID-19: An Evidence-Based Review. *Am J Clin Dermatol* 21: 627-639.
27. Ricardo Criado P, Pincelli TPH, Criado RFJ, Abdalla BMZ, Belda Junior W (2020) Potential interactions of SARS-CoV-2 with human cell receptors in the skin: Understanding the enigma for a lower frequency of skin lesions compared to other tissues. *Exp Dermatol* 29: 936-944.
28. Amatore F, Macagno N, Mailhe M, Demarez B, Gaudy-Marqueste C, et al. (2020) SARS-CoV-2 infection presenting as a febrile rash. *J Eur Acad Dermatol Venereol* 34: e304-e306.
29. Ahouach B, Harent S, Ullmer A, Martres P, Begon E, et al. (2020) Cutaneous lesions in a patient with COVID-19: are they related?. *Br J Dermatol* 183: e31.
30. Gianotti R, Veraldi S, Recalcati S, Cusini M, Ghislanzoni M, et al. (2020) Cutaneous Clinico-Pathological Findings in three COVID-19-Positive Patients Observed in the Metropolitan Area of Milan, Italy. *Acta Derm Venereol* 100: adv00124.
31. Kanitakis J, Lesort C, Danset M, Jullien D (2020) Chilblain-like acral lesions during the COVID-19 pandemic ("COVID toes"): Histologic, immunofluorescence, and immunohistochemical study of 17 cases. *J Am Acad Dermatol* 83: 870-875.
32. Sanchez A, Sohier P, Benganhem S, L'Honneur AS, Rozenberg F, et al. (2020) Digitate Papulosquamous Eruption Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *JAMA Dermatol* 156: 819-820.
33. Criado PR, de Carvalho JF, Ayabe LA, Brandt HR, Romiti R, et al. (2012) Urticaria and dermographism in patients with adult-onset Still's disease. *Rheumatol Int* 32: 2551-2555.

Citation: Fernández-Guarino M, Stewart V, Fernández-Nieto D, del Real MG, González-de-Olano D, et al. (2024) Generalized Rash in Severe Hospitalized COVID Patients: Correlation Between Histological Examinations, Drug Intake, Blood Interleukins Profile and Long-Term Follow-Up. *Int J Nurs Health Care Res* 7:1569. DOI: <https://doi.org/10.29011/2688-951.101569>

34. Llamas-Velasco M, Munoz-Hernandez P, Lazaro-Gonzalez J, Reolid-Perez A, Abad-Santamaria B, et al. (2020) Thrombotic occlusive vasculopathy in a skin biopsy from a livedoid lesion of a patient with COVID-19. *Br J Dermatol* 183: 591-593.
35. Torrelo A, Andina D, Santonja C, Noguera-Morel L, Bascuas-Arribas M, et al. (2020) Erythema multiforme-like lesions in children and COVID-19. *Pediatr Dermatol* 37: 442-446.
36. Llamas-Velasco M, Fraga J, Rodriguez-Villa Lario A, Catala A, Perez-Gonzalez YC, et al. (2023) A Series of 69 COVID-related Dermatoses With Biopsy, Immunohistochemistry With Anti-spike 3, in situ Hybridization and PCR: A Critical Reappraisal of Viral Involvement in COVID-19 Skin Lesions. *Actas Dermosifiliogr* 114: 747-754.
37. Marzano AV, Moltrasio C, Genovese G, De Andrea M, Caneparo V, et al. (2023) SARS-CoV-2 Detection by Digital Polymerase Chain Reaction and Immunohistochemistry in Skin Biopsies from 52 Patients with Different COVID-19-Associated Cutaneous Phenotypes. *Dermatology*. 239: 584-591.
38. Arturi F, Melegari G, Giansante A, Giuliani E, Bertellini E, et al. (2023) COVID-19 Biomarkers for Critically Ill Patients: A Compendium for the Physician. *Neurol Int* 15: 881-895.
39. Granai M, Warm V, Vogelsberg A, Milla J, Greif K, et al. (2023) Impact of P-selectin-PSGL-1 Axis on Platelet-Endothelium-Leukocyte Interactions in Fatal COVID-19. *Lab Invest*. 103: 100179.
40. Simons P, Rinaldi DA, Bondu V, Kell AM, Bradfute S, et al. (2021) Integrin activation is an essential component of SARS-CoV-2 infection. *Sci Rep* 11: 20398.
41. Schiuma G, Beltrami S, Bortolotti D, Rizzo S, Rizzo R (2022) Innate Immune Response in SARS-CoV-2 Infection. *Microorganisms*, 10.
42. Ricci D, Etna MP, Rizzo F, Sandini S, Severa M, et al. (2021) Innate Immune Response to SARS-CoV-2 Infection: From Cells to Soluble Mediators. *Int J Mol Sci* 22.
43. Frumholtz L, Bouaziz JD, Battistella M, Hadjadj J, Chocron R, et al. (2021) Type I interferon response and vascular alteration in chilblain-like lesions during the COVID-19 outbreak. *Br J Dermatol* 185: 1176-1185.
44. Ong EZ, Chan YFZ, Leong WY, Lee NMY, Kalimuddin S, et al. (2020) A Dynamic Immune Response Shapes COVID-19 Progression. *Cell Host Microbe*. 27: 879-882 e872.

Appendix A

Interleukin (IL)	Before	After	P value
IL6	970.6 ± 626.8	283.9 ± 186.5	p>0.005
TNFα	3.802 ± 0.84	9.367 ± 1.154	p<0.005
IL12	0.9306 ± 0.39	1.344 ± 0.24	p>0.005
INFγ	1.857 ± 0.48	2.168 ± 0.82	p>0.005
IL17	0.470 ± 0.09	1.095 ± 0.11	p>0.005

IL: interleukin; TNFα: Tumor necrosis factor alpha; INFγ: Interferon gamma

Table A1: Means and standard error of inflammatory interleukins compared before and after the cutaneous lesions.

Interleukin	Group 1 Dermatitis	Group 2 Drug reaction	Group 3 Vasculitis
IL6 before	150.7 ± 78.74	3756 ± 2345¹	70.64 ± 21.81
IL6 after	60,89 ± 23,74	95,99 ± 14,18	1640 ± 1408²
TNFα before	4.053 ± 1.46	3.430 ± 2.16	3.798 ± 1.14
TNFα after	4.690 ± 1.29	13.43 ± 1.27³	5.818 ± 2.49

Citation: Fernández-Guarino M, Stewart V, Fernández-Nieto D, del Real MG, González-de-Olano D, et al. (2024) Generalized Rash in Severe Hospitalized COVID Patients: Correlation Between Histological Examinations, Drug Intake, Blood Interleukins Profile and Long-Term Follow-Up. *Int J Nurs Health Care Res* 7:1569. DOI: <https://doi.org/10.29011/2688-951.101569>

IL12 before	0.1943 ± 0.12	2.165 ± 1.33	0.9667 ± 0.59
IL12 after	0,6590 ± 0.29	1.564 ± 0.26⁴	2.120 ± 1.29
INFγ before	1.935 ± 0.68	3.350 ± 0.00	0.9550 ± 0.24
INFγ after	0.6783 ± 0,29	2.947 ± 1.28⁵	1.247 ± 0.67
IL17 before	0.4400 ± 0.15	0.710 ± 0.00	0.4100 ± 0.04
IL17 after	0.7867 ± 0.23	1.331 ± 0.12⁶	0.5267 ± 0.05
P with statistically significant differences between groups: 1: Basal levels of IL6 in Group 1; 2: IL6 after cutaneous lesions in Group 3; 3:TNFα after cutaneous lesions in Group 2; 4: IL12 after cutaneous lesions in comparison with Group 1; 5: INFγ after cutaneous lesions in Group 2; 6: IL17 after cutaneous lesions in Group 2.			

Table A2: Means and standard error of inflammatory interleukins compared between groups before and after the cutaneous lesions.